Navigation Links
Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial
Date:5/13/2009

SAN DIEGO, May 13 /PRNewswire/ -- Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.

"This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results."

About GRAVITAS

The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company's VerifyNow System reduces major cardiovascular adverse events post-PCI.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix, ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., Plavix is a registered trademark of Sanofi-Aventis, ReoPro is a registered trademark of Centocor, Inc., and Integrilin is a registered trademark of Millennium Pharmaceuticals.

    CONTACT:
    Jules Abraham
    Lippert/Heilshorn & Associates
    212-838-3777
    jabraham@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    858-404-8260
    press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Accumetrics, Inc. Announces United Kingdom Distribution Agreement With ELITech UK Limited
2. Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
3. Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
4. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
5. St. Lukes Episcopal Hospital Announces Latest Phase of Efficiency, Excellence and Engagement Campaign
6. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
7. HealthWorldNet.com Announces HealthWiNs Awards
8. China Medicine Announces First Quarter 2009 Results
9. Misonix Announces Participation in Annual Diabetic Foot Global Conference
10. Pregis Announces First Quarter 2009 Financial Results
11. BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... ... Doctors on Liens is continuing its steady expansion of medical specialties throughout ... North Valley Eye Medical Group in Mission Hills . Eye injuries and vision ... cases. These injuries have a major impact on the quality of life of ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever ... as organizations, advocates, and individuals join together to increase recognition about the risks ... save lives. , “Today we mark a nationwide movement to raise awareness about ...
(Date:2/22/2017)... ... 22, 2017 , ... Bellus Medical, a leader in medical ... delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians in ... synthesis and provide a faster and more efficient healing process. There are many ...
(Date:2/22/2017)... ... 22, 2017 , ... The SeniorCare Investor will host an important webinar— Seniors ... 2017, at 1:00 PM ET. A recording of the webinar will also be made ... , If you want to find out what really happened in the seniors housing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... suffer from combat-related PTSD. , Established in 1977, our organization was at the ... of military returning to civilian life were evident and served as the catalyst ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb. 22, 2017 IRIDEX Corporation ... will release financial results for the fourth quarter and ... 8, 2017.  The Company,s management team will host a ... 5:00 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:2/22/2017)... astic drugs develop from traditional single antineoplastic drug towards ... at multiple links. Research and development of antineoplastic drugs ... Download the full report: https://www.reportbuyer.com/product/4696059/ ... new tumors in China every ... industrialization and lifestyles changed by factors like urbanization, malignant ...
(Date:2/22/2017)... Summary Provides understanding and access ... agreements entered into by the worlds leading healthcare companies. ... Description The Global Non-Small Cell Lung Cancer Partnering Terms ... to partnering deals and agreements entered into by the ... partnering deals - Top deals by value ...
Breaking Medicine Technology: